The AlphaLISA® EGF/EGFR Binding Kit is designed for the detection of binding activity between Human EGF and EGFR, using a homogeneous AlphaLISA assay (no wash steps). This assay can facilitate the design and development of therapeutics which competitively inhibit the EGF/EGFR interaction.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
|Part Number||Unit Size||List Price||Your Price||Quantity|
|AL366HV||100 assay points||675.00 USD|
|AL366C||500 assay points||1433.00 USD|
|AL366F||5,000 assay points||9500.00 USD|
You successfully added item(s) to your cart
This kit is designed for the detection of binding activity between EGF and EGFR using a homogeneous AlphaLISA® assay (no wash steps). This assay can facilitate the design and development of therapetics by using competitive binding.
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In this AlphaLISA assay, a biotinylated EGF binds to the Streptavidin-coated Alpha Donor beads, while EGFR-Fc is captured by Anti-Human IgG Fc-specific AlphaLISA Acceptor beads. When EGF is bound to EGFR, Donor beads and Acceptor beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfers in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Epidermal Growth Factor Receptor (EGFR, Her1, ErbB1) is a 134 kDa cell surface receptor, part of a four member subfamily of receptor tyrosine kinases (erbB1, erbB2, erbB3, and erbB4). EGFR binds to a family of proteins called the epidermal growth factors (primarily EGF), which, upon association induces dimerization of the receptor and initiates signal transduction for the promotion of cell survival and growth. Mutations that cause aberrant overexpression of EGF and/or EGFR have been linked with many different cancers such as non-small-cell lung and colon cancers. Drugs are being developed as a means to better treat these types cancer.
Disclaimer: For research use only. Not for use in diagnostic procedures.
|Assay Target||EGF, EGFR|
|Assay Target Class||Protein|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||500 assay points|
|Resource Type||File Name||File Format|
|Brochure||Alpha product listing||PDF 124 KB|
|Manual||AlphaLISA EGF-EGFR Binding Kit AL366||PDF 505 KB|
|Event||Society of Laboratory Automation & Screening (SLAS)|